For the Inventor, By the Inventor

Enter assignee name

Neovacs

USPTO Granted Patents = 21

% Expired Patents = 28.6

CIPO Patents = 2

EPO Patents = 7

Trademarks = 2

Forward Citations = 89

Loading Chart...

Loading Chart...

26 inventors (with patents filed for the assignee):

Daniel Zagury (17 out of 25 patents)

Bernard Bizzini (7 out of 9 patents)

Jean-François Zagury (3 out of 6 patents)

4. Hélène Le Buanec (3 out of 3 patents)

5. Helene Le Buanec (2 out of 4 patents)

6. Jay F Rappaport (2 out of 7 patents)

7. Jean-Francois Zagury (2 out of 13 patents)

8. Helene Le Buannec (2 out of 2 patents)

9. Miguel Carcagno (2 out of 2 patents)

10. Jean-François Zagury (2 out of 2 patents)

11. Jean-Francedillaois Zagury (2 out of 2 patents)

12. Géraldine Grouard-vogel (2 out of 2 patents)

13. Noémie Caillot (1 out of 2 patents)

14. Vincent Serra (1 out of 7 patents)

15. Pierre Vandepapeliere (1 out of 4 patents)

21 patents: Sort by Forward Citations

1. 12059457 - Immunogenic product comprising IL-4 and/or IL-13 for treating disorders associated with aberrant IL-4 and/or IL 13 expression or activity (2024-08-13),

2. 9993565 - Method for treating IFNalpha related conditions (2018-06-12),

3. 8697047 - Stable immunogenic product comprising antigenic heterocomplexes (2014-04-15),

4. 8679483 - High-yield method for the production of human antibodies blocking the biological activity of a human cytokine (2014-03-25),

5. 8372388 - Method for preparing a stable TNF-α vaccine (2013-02-12),

6. 8101165 - Use of immunogens to treat or prevent, in malignant tumors, the immune or vascular disorders induced by extracellular factors (2012-01-24),

7. 7972603 - Stable immunogenic product comprising antigenic heterocomplexes (2011-07-05),

8. 7887811 - Method for preparing a stable immunogenic product comprising antigenic heterocomplexes of TNFα and a carrier protein (2011-02-15),

9. 7504479 - Use of immunogenic immunosuppressive and/or angiogenic proteins which have been rendered inactive, process for their preparation and pharmaceutical or vaccinal uses (2009-03-17),

10. 7351554 - Use of inactive immunosuppressive and/or angiogenic immunogenic proteins, for producing secretory IgA's (2008-04-01),

11. 7314629 - Non-immunosuppressive immunogenic or vaccine composition comprising a mutated E7 protein of the HPV-16 virus (2008-01-01),

12. 7022482 - Use of immunogenic immunosuppressive and/or angiogenic proteins which have been rendered inactive, process for their preparation and pharmaceutical or vaccinal uses (2006-04-04),

13. 7022326 - Carboxymethylated retroviral regulatory proteins and interferon-α (2006-04-04),

14. 7015016 - Use of inactivated immunosuppressive or angiogenic immunogenic proteins for producing secretory IgA's (2006-03-21),

15. 6878370 - Chemically modified TNF-α (2005-04-12),

Neovacs is a biotechnology company involved in the development of vaccines and immunotherapies for the treatment of autoimmune and inflammatory diseases, such as lupus and dermatomyositis. The company's innovative technology platform focuses on stimulating the immune system to produce specific targeted antibodies, providing a potential solution for patients with limited treatment options. With a strong pipeline of candidates and ongoing clinical trials, Neovacs strives to address unmet medical needs and improve the lives of patients worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

21 Patents

#228 in Paris

#970 in France

#29,850 in the World

Neovacs

Forward Citations = 89

26 inventors:

Daniel Zagury (17 out of 25 patents)

Bernard Bizzini (7 out of 9 patents)

Jean-François Zagury (3 out of 6 patents)

4. Hélène Le Buanec (3 out of 3 patents)

5. Helene Le Buanec (2 out of 4 patents)

Please report any incorrect information to [email protected]

Loading…